---
category: news
title: "Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma"
excerpt: "PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR Â® artificial intelligence (\"A.I.\") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics,"
publishedDateTime: 2021-01-04T12:00:00Z
originalUrl: "https://www.benzinga.com/pressreleases/21/01/n18996374/lantern-pharma-announces-launch-of-antibody-drug-conjugate-adc-program-to-target-solid-tumors-bloo"
webUrl: "https://www.benzinga.com/pressreleases/21/01/n18996374/lantern-pharma-announces-launch-of-antibody-drug-conjugate-adc-program-to-target-solid-tumors-bloo"
ampWebUrl: "https://amp.benzinga.com/amp/content/18996374"
cdnAmpWebUrl: "https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/18996374"
type: article
quality: 5
heat: 5
published: false

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg"
    width: 400
    height: 296
    isCached: true

secured: "Ro6YgG3KZ0wp/FkUXbIQR8IMqwkh5VEV1O3Zw3fsoc4EpIWWZ25wEIneg4OPNlgDFtHj0o3wlDjkE/CrXW5sOsagM2M5v1xFyDjaHXmLZETZMf/S5mqW1dftZtWn4Ig6tsvyxV8ydMnXY3p+2kJwSuXjOHtNKbAMu8yZNkQ52ifxEYZkQYX9bBt7wqZeh+kTYVdNdcSI7V8qOslH22vI/W6z6SyFuUnr9CYxUWekT9zFmHbgm3jRFzdQrXSRTpIM4odjAm2NkL4J/kL9syF1iOCRrFC/wrGBn4gTDU2F0DneYPdhl4JIm7yWPAlGRzJS4xr9N7bv0tuXGSO3cOEioRpEZpKCnTaf6u62Xq2+x3A=;kdADynZGySxyowI+OS8CxQ=="
---

